The Covid vaccine mix produces as much or more antibodies than using the same vaccine as a booster, according to preliminary results from a much-anticipated US government-sponsored trial.
The trial is the first large US study to compare the effects of using different vaccines as boosters from the initial injection (s). The complicated 9-arm trial involved more than 450 people and measured the effects of a booster injection of Moderna Inc., Pfizer Inc.-BioNTech SE or Johnson & Johnson vaccines on those who had initially received a different vaccine.
Overall, the results revealed that mixing and pairing resulted in comparable or higher levels of neutralizing antibodies compared to the same vaccine booster, the researchers said in the prepublication posted on medRxiv.org. Adverse event rates were similar across all different booster groups, according to the study.
“These data suggest that if a vaccine is approved or authorized as a booster, an immune response will be generated regardless of the primary vaccination schedule against Covid-19,” the researchers said in their conclusion.
The results of the ongoing trial have yet to be peer reviewed and published in a medical journal. More details about the study are expected to be released Friday afternoon at an FDA advisory group meeting, where the researchers leading the trial are due to make a presentation on their early findings.
Mixing and matching boosters has become an increasingly important issue. Many countries outside of the United States have used the method in an attempt to maximize vaccine effectiveness or to avoid rare side effects associated with certain vaccines.
In the United States, some people who have been injected with Johnson & Johnson may be interested in having an injection of messenger RNA as a booster. Also, mixing and pairing could make it easier for authorities to roll out the boosters, as people receiving the boosters could have any Covid vaccine handy in their pharmacy and would not have to search for the vaccine. specific that they had previously received.
Outside of the United States, concerns about rare blood clots associated with AstraZeneca Plc vaccine have led many countries in Europe to suspend use of the vaccine and give a different second dose instead. In the UK, health authorities have implemented a booster program for an extra dose of Pfizer vaccine as a preferred option, and have also offered a half-dose of Moderna vaccine as an alternative.
(Except for the title, this story was not edited by DAILYNEWSCATCH staff and is posted from a syndicated feed.)